Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Optimer Pharmaceuticals, a biopharmaceutical company, has reported that the US Patent and Trademark Office has issued a production patent covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase III clinical trial for the treatment of Clostridium difficile infection, or CDI.
Subscribe to our email newsletter
According to Optimer, Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile.
Michael Chang, president and CEO of Optimer, said: “The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin. We believe this patent and the issued polymorphic form A patent, along with additional pending patent applications, will enhance our intellectual property protection for fidaxomicin.”